Navigation Links
NOVAVAX and University of Massachusetts Medical School Publish Preclinical Safety and Efficacy Study of a Respiratory Syncytial Virus (RSV) Virus-like Particle (VLP) Vaccine Candidate
Date:12/22/2010

disease from the molecular level to large-scale clinical trials. Basic and clinical research has led to new approaches for diagnosis, treatment and prevention of disease. Visit www.umassmed.edu for additional information.

About Novavax

Novavax, Inc. is a clinical-stage biopharmaceutical company creating novel vaccines to address a broad range of infectious diseases worldwide, including H1N1, using advanced proprietary virus-like-particle (VLP) technology. The company produces potent VLP-based recombinant vaccines utilizing new and efficient manufacturing approaches. Novavax is committed to using its VLP technology to create country-specific vaccine solutions. The company has formed a joint venture with Cadila Pharmaceuticals, named CPL Biologicals, to develop and manufacture vaccines, biological therapeutics and diagnostics in India. Additional information about Novavax is available on the company's website: www.novavax.com.

Cautionary Note Regarding Forward-Looking Statements

Statements herein relating to the results of preclinical tests are forward-looking statements. Novavax cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. We caution readers not to place significant reliance on forward-looking statements contained in this release. Factors that may cause actual results to differ materially from the results discussed in forward-looking statements are contained in Novavax's filings with the U.S. Securities and Exchange Commission, which are available at www.sec.gov, including the factors discussed under the caption "Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended December 31, 2009, as updated by our Quarterly Reports on Form 10-Q for the quarters ended March 31, 2010, June 30, 2010, and September 30, 20
'/>"/>

SOURCE Novavax, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. NOVAVAX Awarded Nearly $1 Million in Grants from IRS Under Qualifying Therapeutic Discovery Project
2. NOVAVAX to Present at the Immunotherapeutics and Vaccine (IMVAC) Summit
3. NOVAVAX Elects Richard H. Douglas to its Board of Directors
4. Novavax Announces Appointment of Dr. Gregory Glenn as Chief Scientific Officer
5. Novavax Announces Manufacturing Management Appointments
6. Novavax Announces Publication of a Pre-clinical Study with its Pandemic 2009 H1N1 Influenza Virus-Like Particle (VLP) Vaccine
7. NOVAVAX Completes Enrollment of Pivotal H1N1 Influenza Vaccine Clinical Trial in Mexico
8. NOVAVAX to Present at the 12th Annual BIO CEO & Investor Conference
9. NOVAVAX to Present at Phacilitate Vaccine Forum Washington 2010
10. NOVAVAX Announces Positive Preclinical Results for its Respiratory Syncytial Virus (RSV) Vaccine Candidate
11. NOVAVAX to Present at the Piper Jaffray 21st Annual Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... in German . ... dots in a semiconductor layer. Quantum dots are small structures ... If a short laser pulse is fired at the photonic ... experiences a change in the electromagnetic field around it. This ... light by the dot. As soon as the refractive index ...
(Date:9/30/2014)... Using a bio-mimicking analog of one of nature,s ... international research team led by Alejandro Briseno of ... major step in developing long-sought polymer architecture to ... use in electronic devices. , Briseno, with ... others at Stanford University and Dresden University of ...
(Date:9/30/2014)... 30, 2014 Shimadzu Scientific Instruments ... easy-to-use and highly precise tool for measuring displacement ... elongation. With 1000-mm maximum movement distance, the DSES-1000 ... a gauge length of 10 mm. In addition, ... above 50-mm stroke and within +/- 100 µm ...
(Date:9/30/2014)... (PRWEB) September 30, 2014 Proove ... medicine, is excited to announce a new genetic test ... The Proove Pain Perception Test will provide physicians ... and why pain tolerance levels are stratified between individuals. ... identify whether a person has a genetic predisposition that ...
Breaking Biology Technology:Ultrafast remote switching of light emission 2Blades of grass inspire advance in organic solar cells 2Blades of grass inspire advance in organic solar cells 3Shimadzu’s New Long-Travel Extensometer Increases Precision for Soft Material Testing 2Proove Biosciences is Now Offering the Proove Pain Perception Genetic Test to Help Physicians Assess Patient Pain Tolerance Levels 2Proove Biosciences is Now Offering the Proove Pain Perception Genetic Test to Help Physicians Assess Patient Pain Tolerance Levels 3
... - YM BioSciences Inc. (NYSE Amex: YMI ... company that identifies and advances a diverse portfolio ... development, today reported that its licensee for nimotuzumab, ... has commenced enrollment of a Phase II trial ...
... and to Complete Current Phase 3 Trial of Naturlose(R) ... June 23 Spherix Incorporated (Nasdaq: SPEX ... a provider of technical and regulatory consulting services to ... it has received its first full-scale production batch of ...
... Medical Device & Diagnostic Industry Magazine,s 30 Years, 30 Devices Special ... 23 Medical Device and Diagnostic Industry has recognized ... a leader in infusion therapy and pain management as well as ... as being among the most influential medical devices of the last ...
Cached Biology Technology:YM BIOSCIENCES REPORTS DAIICHI-SANKYO ENROLLS FIRST PATIENTS IN PHASE II, FIRST-LINE LUNG CANCER TRIAL WITH NIMOTUZUMAB 2YM BIOSCIENCES REPORTS DAIICHI-SANKYO ENROLLS FIRST PATIENTS IN PHASE II, FIRST-LINE LUNG CANCER TRIAL WITH NIMOTUZUMAB 3YM BIOSCIENCES REPORTS DAIICHI-SANKYO ENROLLS FIRST PATIENTS IN PHASE II, FIRST-LINE LUNG CANCER TRIAL WITH NIMOTUZUMAB 4YM BIOSCIENCES REPORTS DAIICHI-SANKYO ENROLLS FIRST PATIENTS IN PHASE II, FIRST-LINE LUNG CANCER TRIAL WITH NIMOTUZUMAB 5Spherix Announces Full-Scale Production of Pharmaceutical Tagatose 2Spherix Announces Full-Scale Production of Pharmaceutical Tagatose 3Spherix Announces Full-Scale Production of Pharmaceutical Tagatose 4B. Braun Medical Inc. Recognized by Industry for Manufacturing Influential Medical Devices 2B. Braun Medical Inc. Recognized by Industry for Manufacturing Influential Medical Devices 3B. Braun Medical Inc. Recognized by Industry for Manufacturing Influential Medical Devices 4
(Date:9/29/2014)... Washington, DC Monday, September 29: Between 1970 ... and fish around the globe dropped 52 percent, ... by World Wildlife Fund (WWF). This biodiversity loss ... increasing resource use of high-income countries. , In ... the report,s data point to other warning signs ...
(Date:9/29/2014)... school? According to a new Food and Brand Lab ... can increase participation in the National School Lunch Program ... vegetables by 16%! , Chefs Move to Schools (CMTS), ... chefs with schools in order to provide nutrition instruction ... service workers. , A CMTS event was held in ...
(Date:9/29/2014)... team says recently identified radiation detection properties of a ... for homeland security and medical advances. , In a ... of Optics Letters , UT Arlington Physics Professor ... to fabricate transparent nanoscintillators by heating nanoparticles composed of ... formed. A scintillator refers to a material that ...
Breaking Biology News(10 mins):Half of global wildlife lost, says new WWF report 2Chefs move to schools can increase school meal participation and vegetable intake among students 2UT Arlington researchers develop new transparent nanoscintillators for radiation detection 2UT Arlington researchers develop new transparent nanoscintillators for radiation detection 3
... y MUNICH, 7 de noviembre de 2012 Bausch + ... ejercitación de su opción de compra de todas las acciones ... Vision GmbH (TPV), una destacada compañía láser de oftalmología. ... de una sociedad mixta entre Bausch + Lomb y 20/10 ...
... 2012 Bausch + Lomb, a empresa global de saúde ... as ações em circulação e sem controle da Technolas ... A Technolas Perfect Vision foi criada em 2009 ... + Lomb e a 20/10 PERFECT VISION AG para desenvolver ...
... well known for attacking a protein associated with the ... it also degraded a different protein that triggers blood ... a key challenge in the battle against cancer, according ... in the University of Leeds, Faculty of Biological Sciences., ...
Cached Biology News:Bausch + Lomb adquiere Technolas Perfect Vision GmbH 2Bausch + Lomb adquiere Technolas Perfect Vision GmbH 3Bausch + Lomb adquiere Technolas Perfect Vision GmbH 4Bausch + Lomb prestes a adquirir a Technolas Perfect Vision GmbH 2Bausch + Lomb prestes a adquirir a Technolas Perfect Vision GmbH 3Bausch + Lomb prestes a adquirir a Technolas Perfect Vision GmbH 4Breast cancer drug could halt other tumors 2
Rabbit polyclonal to hnRNP-U...
... iTaq DNA polymerase is ... suitable for both conventional and ... is supplied at a concentration ... and includes 250 units polymerase, ...
... (E.C. 3.1.21.1) is a nonspecific endonuclease that ... functions by hydrolyzing phosphodiester linkages, producing mono ... 3'-hydroxyl group. Ambion's RNase-free DNase I is ... recommended to degrade DNA in the presence ...
RABBIT ANTI RHEB (IN) Immunogen: A 15 amino acid peptide located in the central region of human Rheb....
Biology Products: